Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CI-1040 · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| CI-1040 | DRUG | - |
Inclusion Criteria: * Patients who are at least 18 years or older who have pathological or hiostological confirmation of colorectal, nonsmall cell lung cancer, breast, or pancreas cancer. * No more than 1 prior chemo for lung or colon cancer, no more than 2 for breast no prior chemotherapy for panc...
CI-1040 is an investigational small molecule being studied for the treatment of colorectal neoplasms, as well as breast, non-small-cell lung, and pancreatic cancer. It is in Phase 2 clinical development and has not been approved by the FDA.
CI-1040 is being developed by Pfizer, Inc. (NYSE: PFE). The drug is a small molecule in the oncology therapeutic area, currently in Phase 2 clinical trials.
CI-1040 is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. One Phase 2 study of CI-1040 has been completed.
CI-1040 was studied in a completed Phase 2 clinical trial, NCT00034827, which enrolled 172 patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. The trial was conducted in the United States and included patients aged 18 years and older.
CI-1040 is the primary name for this investigational drug. No alternative names have been reported for it in clinical trial records.